Severe lactic acidosis secondary to minocycline in a teenager with infectious mononucleosis and mitochondrial myopathy

Emergency Department, Presbyterian Intercommunity Hospital of Whittier, Whittier, CA 90602, USA. <>
Clinical Neurology and Neurosurgery (Impact Factor: 1.13). 07/2008; 110(6):627-30. DOI: 10.1016/j.clineuro.2008.03.006
Source: PubMed


Mitochondrial myopathies are heterogeneous disorders with diverse presentations including laboratory findings of lactic acidosis. Often times they are diagnosed in childhood or the early teenage years following an infectious illness. Minocycline is a common antibiotic used for the treatment of acne. It has been reported to alter mitochondrial respiratory chain complexes. We report an interesting case of a teenager in which mitochondrial myopathy with severe lactic acidosis presented following a bout of infectious mononucleosis and minocycline use. It is hypothesized that oxidative stress from the infectious illness plus the minocycline use triggered the patient's presentation. The clinical manifestations and genetics of mitochondrial myopathies and treatment are discussed along with the management of lactic acidosis.

Download full-text


Available from: Richard Alan Rison, Jul 26, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis neuromuscular disorder may apply to numerous rare heterogeneous diseases. While the considerable variation in the clinical picture reflects the wide range of underlying causes, skeletal muscle weakness is usually present. For the anaes - thesiologist, management of these patients is always a challenge, since, although infrequent, the disease is associated with a high rate of perioperative complications. Apart from the choice of anaesthetic procedure there are further considerations regarding the overall perioperative management. What pre-operative information needs to be obtained, what intra-operative monitoring is required and how should postoperative monitoring be organized? Additional considerations should include the management of typical complica-tions, the increased risk of bleeding, and anaesthesia during pregnancy or labour. Although evidence-based answers are usually not available, an exact diagnosis and careful assessment of the underlying pathophysiological mechanisms may help to optimize anaes - thesiological management and reduce the risk for the patient.
    No preview · Article · Apr 2009 · Anasthesiologie und Intensivmedizin
  • [Show abstract] [Hide abstract]
    ABSTRACT: Propofol is an alkylphenol derivative named 2, 6, diisopropylphenol and is a potent intravenous short-acting hypnotic agent. It is commonly used as sedation, as well as an anesthetic agent in both pediatric and adult patient populations. There have been numerous case reports describing a constellation of findings including metabolic derangements and organ system failures known collectively as propofol infusion syndrome (PRIS). Although there is a high mortality associated with PRIS, the precise mechanism of action has yet to be determined. The best preventive measure for this syndrome is awareness and avoidance of clinical scenarios associated with development of PRIS. There is no established treatment for PRIS; care is primarily supportive in nature and may include the full array of advanced cardiopulmonary support, including extracorporeal membrane oxygenation (ECMO). This article reviews the reported cases of PRIS and describes the current understanding of the underlying pathophysiology and treatment options.
    No preview · Article · Apr 2011 · Journal of Intensive Care Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Mitochondrial disorders are a group of metabolic conditions caused by impairment of the oxidative phosphorylation system. The treatment of mitochondrial diseases is still inadequate. Therapies that have been attempted include: respiratory chain cofactors, other metabolites secondarily decreased in mitochondrial disorders, antioxidants, and agents acting on lactic acidosis. However, their role in the treatment of the majority of mitochondrial diseases is still unclear. Furthermore, some drugs may potentially have detrimental effects on mitochondrial dysfunction. AREAS COVERED: To critically review this still unclear field, this paper attempts to answer, on the basis of the basic and clinical literature available to date, the 'frequently asked questions', such as: Is valproic acid safe in mitochondrial patients? What about other antiepileptic drugs? May metformin trigger lactic acidosis in mitochondrial patients? Are statins safe in these subjects? EXPERT OPINION: Randomized clinical trials are necessary to establish efficacy and safety of drugs. Multicenter collaboration is essential for the advancement of therapy for mitochondrial disorders.
    No preview · Article · Mar 2012 · Expert Opinion on Pharmacotherapy
Show more